Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS
Treatment with imetelstat, a competitive inhibitor of telomerase enzymatic activity, was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients...
Precision Medicine Approach Deemed Safe, Feasible for Older Patients With Untreated AML
A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated acute myeloid leukemia...
Ivosidenib and Azacitidine Combination Demonstrates Durable Activity in Newly Diagnosed AML
Ivosidenib, an inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, was well tolerated and associated with deep and durable responses in combination with...
Study Identifies Key Mutations That Promote Stem Cell Growth and Increase Leukemia Risk
In a report published in Nature, researchers linked three genetic loci to the increased proliferation of hematopoietic stem cells (HSCs), which may subsequently increase...
Female Underrepresentation Persists Among Patients Enrolled in Hematologic, Solid Tumor Trials
While clinical trials have increasingly included female participants over the past 40 years, women are underrepresented in clinical trials of cancer treatments compared with...
Optimizing Outcomes With Azacitidine Treatment in Patients With MDS
Delays in treatment with azacitidine predicted lower survival rates in patients with myelodysplastic syndromes (MDS), independently of the International Prognostic Scoring System (IPSS) score...
Fostamatinib More Effective Earlier in Treatment for Immune Thrombocytopenia
Fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, was more effective and had similar safety when used as a second-line therapy, rather than as a...
Ixazomib Maintenance Delays Progression in Non-Transplanted Patients With Newly Diagnosed Myeloma
Postinduction maintenance therapy with the oral proteasome inhibitor ixazomib prolonged progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (MM) who were not...
Treatment With Caplacizumab Allows Patients to Delay or Omit Plasma Exchanges
Treatment of acquired thrombotic thrombocytopenic purpura (aTTP) with caplacizumab, but without plasma exchange, increased platelet counts and improved surrogate parameters of organ damage in...
Pediatric-Inspired Pegaspargase Regimen Shows Promise for Treatment of ALL/LBL
A pediatric-inspired treatment regimen incorporating pegaspargase timed to avoid overlapping toxicities was associated with manageable toxicity, high measurable residual disease (MRD) negativity rates, and...
Current Issue
Mid-January 2021 Annual Meeting Edition
This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.